Areyl Goff, APNP

Dr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific therapy, as well as best practices for transitioning care back to the community center after therapy administration.

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for effectively initiating these discussions with patients.

Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE profiles of talquetamab, teclistamab, and elranatamab, highlighting unique challenges and benefits.

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments significantly impacted patient outcomes.

Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the unique considerations of talquetamab targeting GPRC5D.